Last reviewed · How we verify
Benzylpenicillin - three days
Benzylpenicillin, marketed by Murdoch Childrens Research Institute, holds a position in the antibiotic market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad usage, supported by its marketed status. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Benzylpenicillin - three days |
|---|---|
| Sponsor | Murdoch Childrens Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- A Comparison of Recovery After Impacted Wisdom Tooth Removal (PHASE3)
- Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone (PHASE3)
- A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile (NA)
- Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (PHASE4)
- Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzylpenicillin - three days CI brief — competitive landscape report
- Benzylpenicillin - three days updates RSS · CI watch RSS
- Murdoch Childrens Research Institute portfolio CI